戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  recipient conditioning with an antilymphoid antibody preparation.
2 roid-resistant rejection was managed with an antibody preparation.
3 icient to obtain a modified protein-specific antibody preparation.
4  assess the neutralizing activity of anti-PE antibody preparations.
5 scence microscopy by using several different antibody preparations.
6 to horse and rabbit polyclonal antithymocyte antibody preparations.
7 aluate the relative homogeneity of different antibody preparations.
8 nificantly reduces the use of antilymphocyte antibody preparations.
9 y from IgY fractions of monospecific chicken antibody preparations.
10 sponse is currently reflected in therapeutic antibody preparations.
11 acy of different batches of these polyclonal antibody preparations.
12 rified recombinant proteins were used to for antibodies preparation.
13 from affinity-isolated, monospecific chicken antibody preparations and to measure antibody specifical
14           Immunoglobulins and/or therapeutic antibody preparations are associated with a high rate of
15 practical considerations preclude the use of antibody preparations as a prophylactic passive immuniza
16                   Affinity-purified anti-HMW antibody preparations demonstrated opsonophagocytic tite
17 bulins (AThG) are a subset of antilymphocyte antibody preparations derived from the sera of rabbits o
18                    Radiolysis of 90Y-labeled antibody preparations did not appear to be a problem at
19                                         Both antibody preparations effected the rapid and complete el
20                                        These antibody preparations failed to detect the known TonB ho
21               RSV-IGIV is a polyclonal human antibody preparation for intravenous infusion enriched f
22 tile probes for screening crude and purified antibody preparations for receptor specificity, epitope
23  these data suggest that mucosally delivered antibody preparations may be most effective when combini
24                       Current antivenoms are antibody preparations obtained from the plasma of animal
25             (PE)HRG214 (HRG) is a polyclonal antibody preparation produced by immunization of goats w
26 es for CHS and CHI showed that the resulting antibody preparations provide useful tools for character
27 induction immunosuppression with a depleting antibody preparation reduced rejection, whereas SRL prol
28 tages include: overcoming the variability in antibody preparations; removing the need to use laborato
29 three antibody cocktails, and two polyclonal antibody preparations retained measurable neutralization
30 t and western blot assays are used to assess antibody preparation specificity.
31 be candidates for treatment with a humanized antibody preparation such as daclizumab in the presence
32 th antiviral drugs and the use of polyclonal antibody preparations such as convalescent plasma.
33  mammalian meat excluding primates, and some antibody preparations, such as cetuximab.
34 therapeutic administration of the polyclonal antibody preparations (TcPAbs) can protect mice against
35 e of Rh immune globulin (RhIg), a polyclonal antibody preparation that causes antibody-mediated immun
36 (13% vs. 4%; P=0.03), or to have received an antibody preparation to treat acute rejection (19% vs. 8
37                         For the radiolabeled antibody preparations used in this study, quantitative i
38 g in situ PLA, compared to assays where each antibody preparation was used on its own.
39  and the biodistribution of the radiolabeled antibody preparations was determined.
40 e precision, aggregate content in monoclonal antibody preparations was measured by AUC-SV and analyze
41       None of the affinity-purified anti-HMW antibody preparations was opsonophagocytic for a represe
42                   Biodistribution of the two antibody preparations were remarkably similar with an in